COVID-19 outcomes are worse in male patients. Androgen signaling, therefore, is a target for clinical exploration. TMPRSS2 is a membrane protease required for COVID pathogenesis that is regulated by androgens. Blocking TMPRSS2 with bicalutamide may reduce viral replication and improve the clinical outcome. Therefore, the study proposes to test bicalutamide at 150 mg oral daily dosing in a double-blind placebo-controlled randomized trial in male patients with early symptomatic COVID-19 disease.
Drug: Bicalutamide 150 Mg Oral Tablet
Bicalutamide 150 mg by mouth daily
Drug: Placebo
Placebo as formulated by mouth daily
Inclusion Criteria:
Subjects must meet all of the following criteria to be eligible for study participation:
- Men ≥ 36 years old diagnosed with at least one temperature elevation ≥ 100.4 F., OR
new cough, OR new dyspnea AND documented COVID-19 positive by approved standard local
laboratory assay
- Men ≥ 18 years but < 36 years old must exhibit EITHER new cough, OR new dyspnea AND
documented COVID-19 positive by approved standard local laboratory assay.
- Access to working telephone or other form of communication such as email.
- Randomization within 7 days of COVID-positive study result. All subjects will undergo
repeat COVID-19 assay on day 0 enrollment and a positive test is required to stay on
study
- Written informed consent obtained from the subject and the subject agrees to comply
with all study-related procedures
Exclusion Criteria:
Subjects with any of the following will not be eligible for study participation:
- Randomization greater than 7 days from a positive COVID test result. All subjects will
undergo repeat COVID-19 assay on day 0 enrollment and a negative test will result in a
screen-fail and removal from study
- Admission to hospital at time of screening
- Inclusion in another randomized trial for COVID therapy
- Diagnosis of prostate cancer and/or treatment with anti-androgen in the past 3 months
- Current treatment with any androgen replacement products
- Prior allergic reaction or intolerance to Bicalutamide or other Androgen receptor
Inhibitors
- Requirement for coumarin product or warfarin products due to potential displacement by
bicalutamide
- Subject unable to take oral bicalutamide
- Known Hepatitis B or C
- Liver Cirrhosis
- AST/ALT greater than or equal to 3 X institutional ULN
University of Florida Clinincal Research Vehicle
Gainesville, Florida, 32603
Frederic Kaye, MD, Principal Investigator
University of Florida